Triamcinolone Diacetate

Summary

Triamcinolone Diacetate (CHEMBL1200449) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 478.5 Da · C25H31FO8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200449
Name	Triamcinolone Diacetate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6216
Molecular formula	C25H31FO8
Molecular weight	478.5
InChIKey	XGMPVBXKDAHORN-RBWIMXSLSA-N

SMILES: CC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)OC(=O)C)O

IUPAC name: [2-[(8S,9R,10S,11S,13S,14S,16R,17S)-16-acetyloxy-9-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate

Also known as: Aristocort, Aristocort forte, Kenacort, NSC-757356, Orion, Polcortolon, Triamcinolone diacetate, Tedarol, TRIAMCINOLONE DIACETATE, SID144206670, SID170464837, TRIAMCINOLONE-DIACETATE

Patent coverage: 1,133 distinct patent families (4,301 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).